Basic Study
Copyright ©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Oncol. Mar 24, 2025; 16(3): 101725
Published online Mar 24, 2025. doi: 10.5306/wjco.v16.i3.101725
Checkpoint kinase 1 in colorectal cancer: Upregulation of expression and promotion of cell proliferation
Yu-Yan Pang, Zu-Yuan Chen, Da-Tong Zeng, Dong-Ming Li, Qi Li, Wan-Ying Huang, Bin Li, Jia-Yuan Luo, Bang-Teng Chi, Qiu Huang, Zhen-Bo Feng, Rong-Quan He
Yu-Yan Pang, Zu-Yuan Chen, Dong-Ming Li, Qi Li, Wan-Ying Huang, Bin Li, Jia-Yuan Luo, Bang-Teng Chi, Qiu Huang, Zhen-Bo Feng, Department of Pathology, The First Affiliated Hospital of Guangxi Medical University, Nanning 530021, Guangxi Zhuang Autonomous Region, China
Da-Tong Zeng, Department of Pathology, Redcross Hospital of Yulin City, Yulin 537000, Guangxi Zhuang Autonomous Region, China
Rong-Quan He, Department of Medical Oncology, The First Affiliated Hospital of Guangxi Medical University, Nanning 530021, Guangxi Zhuang Autonomous Region, China
Co-first authors: Yu-Yan Pang and Zu-Yuan Chen.
Co-corresponding authors: Rong-Quan He and Zhen-Bo Feng.
Author contributions: Pang YY, Chen ZY, Zeng DT, Li DM, Li Q, Huang WY, Li B, Luo JY, Chi BT, Huang Q, Feng ZB, He RQ participated in the conception and designed the research study and performed the research; Pang YY and Chen ZY wrote the manuscript; Pang YY, Chen ZY and Zeng DT accessed and verified the study data. All authors critically reviewed and provided final approval of the manuscript; all authors were responsible for the decision to submit the manuscript for publication.
Supported by Innovation Project of Guangxi Graduate Education, No. YCBZ2023096; Guangxi Zhuang Autonomous Region Health Commission Scientific Research Project, No. Z20210442; China Undergraduate Innovation and Entrepreneurship Training Program, No. S202410598185; Future Academic Star of Guangxi Medical University, No. WLXSZX24101.
Institutional review board statement: This investigation was approved by the Institutional Ethics Committee of Yulin Red Cross Hospital.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Data sharing statement: No additional data are available.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Zhen-Bo Feng, PhD, Doctor, Department of Pathology, The First Affiliated Hospital of Guangxi Medical University, Shuangyong Road, Nanning 530021, Guangxi Zhuang Autonomous Region, China. fengzhenbo_gxmu@163.com
Received: September 25, 2024
Revised: November 4, 2024
Accepted: December 6, 2024
Published online: March 24, 2025
Processing time: 118 Days and 19.4 Hours
Core Tip

Core Tip: This study demonstrates that checkpoint kinase 1 (CHEK1) is comparatively overexpressed in colorectal cancer (CRC) and is closely associated with tumor proliferation. Based on single-cell RNA sequencing and immunohistochemistry, the findings highlight CHEK1’s potential as a novel biomarker and therapeutic target in CRC. Furthermore, the research uncovers nitidine chloride as a specific CHEK1 inhibitor, suggesting promising avenues for targeted therapies to improve patient outcomes. These insights underscore the clinical relevance of CHEK1 in CRC management and the need for further exploration of its mechanistic roles.